The new facility will provide StemCyte with increased storage capacity for its supply of plasma-depleted umbilical cord blood (UCB) stem cell products. In addition, the Covina facility will house StemCyte executives and researchers.
In addition to Covina, StemCyte’s operations are located in New Jersey and Taiwan. The company is also developing StemCyte India Therapeutics in Ahmedabad in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.
Kenneth Giacin, chairman and CEO of StemCyte, said: “The new Covina facility is an integral part of our plan to build the largest, most diverse supply of UCB stem cell products to ensure we are able to treat even more patients.”